Dr. David  A. Johnson
My Social Links

Dr. David A. Johnson

Eastern Virginia Medical School, USA

Highest Degree
M.D. in Psychology from University of Virginia, USA

Share this Profile

Area of Interest:

Biomedical Sciences

Research Publications in Numbers


Selected Publications

  1. Toghanian, S., D.A. Johnson and S. Bolge, 2010. The burden of disrupting gastroesophageal reflux disease: A database study in us and european cohorts. Clin. Drug Invest., 30: 167-178.
  2. Johnson, D.A., J. Crawley, C. Hwang and K. Brown, 2010. Clinical trial of esomprazole for moderate to severe nighttime heartburn and gastro-oesophageal reflux related sleep disturbances- a randomized controlled trial with esomeprazole. Aliment Pharmacol. Ther., 32: 182-190.
    CrossRef  |  
  3. Johnson, D.A. and B.H. Levy, 2010. Evolving drugs in gastroesophageal reflux disease: Pharmacologic treatment beyond proton pump inhibitors. Exp. Opin., 11: 1541-1548.
    CrossRef  |  
  4. Johnson, D.A., 2009. Questioning virtual colonoscopy. Radiol. Today, 10: 5-7.
  5. Wahlqvist, P., M. Karlsson, D. Johnson, J. Carlsson, S.C. Bolge and M.A. Wallander, 2008. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: Survey of a US cohort. Aliment Pharmacol. Ther., 27: 960-970.
    CrossRef  |  
  6. Sharma, P. and D.A. Johnson, 2008. Multicultural issues in gastroesophageal reflux disease: A systematic review. Am. J. Gastroenterol., 103: 2669-2680.
  7. Schiller, L. and D.A. Johnson, 2008. FDA and drug recall decisions. Am. J. Gastroenterol., 103: 815-819.
  8. Johnson, D.A., 2008. Medical therapy of reflux laryngitis. J. Clin. Gastroenterol., 42: 589-593.
    CrossRef  |  
  9. Johnson, D.A., 2008. Medical therapy for suspected GERD laryngitis. Clin. Gastro, 43: 589-594.
  10. Itzkowitz, S., R. Brand, L. Jandorf, K. Durkee and J. Millholland et al., 2008. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol., 103: 2862-2870.
    CrossRef  |  
  11. Bhatt, D., J. Schieman, N. Abraham and D.A. Johnson, 2008. Multisociety position consensus on antiplatelet/NSAID therapy in cardiology patients with GI risk. Am. J. Gastroenterol., 103: 2890-2907.
  12. Johnson, D.A., 2006. Treating chronic constipation: How should we interpret the recommendations? Clin. Drug Invest., 26: 547-557.
    PubMed  |  
  13. Devault, K., J. Johanssen and D.A. Johnson, 2006. Esomeprazole versus lansoprazole for maintenance therapy for GERD-a prospective controlled trial. Clin. Gastro Hepatol., 4: 852-859.
  14. Schwegher, E., L. Cazares, L. Steele, D.A. Johnson and R. Drake, 2005. Seldi TOF-MS profiling for detection of progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41: 634-642.
  15. Levin, T.R., J. Bond, S. Winawer, D. Rex and D. Johnson, 2005. Quality in the technical performance of Flexible sigmoidoscopy: Recommendations of an international multisociety task force. Gut, 54: 807-813.
  16. Kim, H.N., R.D. Vorona, M.P. Winn, M. Doviak, D.A. Johnson and J.C. Ware, 2005. Symptoms of gastro-oesophageal reflux disease and the severity of obstructive sleep apnoea syndrome are not related in sleep disorders center patients. Aliment Pharmacol. Ther., 35: 1127-1133.
    PubMed  |  
  17. Johnson, D.A., W. Orr and B. Taxler, 2005. Sleep dysfunction in gastroesophageal reflux disease- a randomized multicenter controlled trial with esomeprazole. Am. J. Gastroenterol., 100: 1914-1922.
  18. Johnson, D.A., 2005. Obesity issues for gastroenterologists. Gastroenterol. Clin. N. Am., 34: 6-9.
  19. Johnson, D.A., 2005. Medical Therapy for GERD: Defining Appropriate Outcomes and Management Strategies. In: Failed Antireflux Therapy: Evaluation and Management, Ferguson, M.K. and M.B. Fennerty (Eds.). Springer-Verlag, London, UK., pp: 31-45.
  20. Johnson, D.A., 2005. Enteryx implant for gastroesophageal reflux disease. Curr. Treat Options Gastroenterol., 8: 51-57.
    PubMed  |  
  21. Johnson, D.A., 2005. Enteryx for gastroesophageal reflux disease. Expert Rev. Med. Devices, 2: 19-26.
  22. Johnson, D.A., 2005. Endoscopic therapy for GERD: Becoming an attractive option? World Gastro, 10: 13-16.
  23. Johnson, D.A., 2005. Endoluminal therapy for GERD-effective and here to stay. AGA Perspectives, 1: 4-9.
  24. Cohen, L., D. Johnson, R. Ganz, J. Aisenberg and J. Deviere et al., 2005. Enteryx implantation for GERD: Expanded multicenter trial results and interim post-approval follow-up to 24 months. Gastrointest Endosc, 61: 650-659.
    PubMed  |  
  25. Vinik, A.I., A. Mehrabyan and D.A. Johnson, 2004. Gastrointestinal Disturbances in Diabetes. In: Therapy for Diabetes Mellitus and Related Disorders, Lebovitz, H.E. (Ed.). American Diabetes Association, USA., pp: 424-39.
  26. Johnson, D.A., 2004. Gastroesophageal reflux disease in the elderly-a prevalent and severe disease. Rev. Gastroenterol. Disord., 4: S16-24.
    PubMed  |  
  27. Johnson, D.A., 2004. Evidence based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis. Exp. Rev. Pharmacoeconomics Outcomes Res., 4: 371-382.
    CrossRef  |  
  28. Johnson, D.A., 2004. Endpoints for the assessment of response to gastroesophageal reflux disease therapy-what are the appropriate measures of ''success''? Rev. Gastroenterol Dis., 4: 118-128.
    PubMed  |  
  29. Johnson, D.A., 2004. Endoscopic therapy for GERD: A systematic review. Minerva Gastroenterol, Dietol., 50: 239-251.
  30. Johnson, D.A., 2004. Acid inhibition-related therapy- gastroesophageal reflux disease and beyond: Hot topics and new insights. Rev. Gastroenterol. Disord., 4: S1-S2.
  31. Johnson, D.A. and M.B. Fennerty, 2004. Effect of Aging on symptom recognition and prevalence of erosive esophagitis. Gastroenterology, 126: 660-664.
  32. Fennerty, M.B. and D.A. Johnson, 2004. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology, 126: 660-664.
    CrossRef  |  PubMed  |  
  33. Chand, N., D.A. Johnson, M. Tabangin and J.C. Ware, 2004. Sleep dysfunction in patients with gastro-oesophageal reflux disease: Prevalence and response to GERD therapy, a pilot study. Aliment Pharm., 20: 969-974.
    PubMed  |  
  34. Johnson, D.A., R. Ganz and J. Aisneberg et al., 2003. Endoscopic, deep mural implantation of ENERYX for the treatment of GERD: 6 month follow-up of a multicenter trial. Am. J. Gastroenterol., 98: 250-258.
  35. Johnson, D.A., 2003. Review of esomeprazole in the treatment of acid disorders. Exp. Opin. Pharmacother., 4: 253-264.
    PubMed  |  
  36. Johnson, D.A., 2003. Endoscopic, deep mural implantation of Enteryx. Am. J. Gastroenterol., 98: 1893-1894.
  37. Johnson, D.A., 2003. Endoscopic therapy for GERD: An evidence based approach. Rev. Gastroenterol. Dis., 3: 142-149.
  38. Johnson, D.A., 2003. Alternative dosing for PPI therapy: Rationale and options. Rev. Gastroenterol. Disord., 3: S10-15.
    PubMed  |  
  39. Johnson, D.A. and A. Roach, 2003. Alternative dosing strategies for esomeprazole. Pharmacotherapy, 23: 731-734.
  40. Rex, D.K., J.H. Bond, S. Winawer, T.R. Levin and R.W. Burt et al., 2002. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: Recommendations of the U.S. multi-society task force on colorectal cancer. Am. J. Gastroenterol., 97: 1296-1308.
    PubMed  |  
  41. Vakil, N.B., R. Shaker, D.A. Johnson, T. Kovacs and R.D. Baerg et al., 2001. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: A 6 month randomized double blind controlled trial. Aliment Pharmacol. Ther., 15: 927-935.
    PubMed  |  
  42. Younes, Z., D.A. Johnson and M.J. Ryan, 2000. GI manifestations of ehrlichiosis. Gastroenterol. Observer, 19: 2-4.
  43. Younes, Z. and D.A. Johnson, 2000. New developments and concepts in antimicrobial therapy for intra abdominal infections. Curr. Gastroenterol. Rep., 2: 277-282.
    PubMed  |  
  44. Rex, D.K., D. Provenzale, D.A. Johnson and D. Lieberman, 2000. Colorectal cancer prevention 2000: Screening recommendations. American college of gastroenterology. Am. J. Gastroenterol., 95: 868-877.
    PubMed  |  
  45. Kahrilas, P.J., D.A. Johnson and J.E. Richter, 2000. Esomeprazole: Effects of a new proton pump inhibitor on gastroesophageal reflux disease. Aliment Pharmacol. Ther., 14: 1267-1272.
  46. Johnson, D.A., Z. Younes and W.J. Hogan, 2000. Endoscopic assessment of hiatal hernia repair. Gastrointest Endosc, 52: 650-659.
    PubMed  |  
  47. Johnson, D.A., Z. Younes and W.H.Hogan, 2000. Endoscopic assessment of anti-reflux repairs. Gastrointest Endosc, 52: 1-10.
  48. Johnson, D.A., R. Ganz, J. Aisenberg, L.B. Cohen and J. Deviere et al., 2000. Endoscopic implantation of Enteryx for GERD treatment: 12 month results of a prospective multicenter trial. Am. J. Gastroenterol., 98: 1921-1930.
    PubMed  |  
  49. Johnson, D.A., J.E. Richter, P.O. Katz, R. Hinder, R. Shaker, S. Santag and N. Flack, 2000. Yale consensus conference on extraesophageal GERD. J. Clin. Gastroenterol., 30: 2-53.
  50. Johnson, D.A., C. Perdomo and J.Barth, 2000. Rabeprazole: Safety profile of the new proton pump inhibitor. Eur. J. Gastroenterol. Hepatol., 12: 1-8.
  51. Johnson, D.A., 2000. Visceral perception: Its role in functional bowel disorder/chest pain. Practical. Gastroenterol., 24: 72-74.
  52. Johnson, D.A., 2000. Consensus conference on gastroesophageal reflux disease. Consensus statement. J. Clin. Gastroenterol., 30: 51-53.
  53. Johnson, D.A. and D.K. Rex, 2000. Colon cancer screening: American college of gastroenterology screening registry. Am. J. Gastroenterol., 95: 868-877.
  54. Younes, Z. and D.A. Johnson, 1999. The spectrum of spontaneous and iatrogenic esophageal injury- perforations, Mallory-Weiss tears and hematomas. J. Clin. Gastroenterol., 29: 306-317.
    PubMed  |  
  55. Younes, Z. and D.A. Johnson, 1999. Congenital esophageal stenosis: Clinical endoscopic features in adults. Dig Dis., 17: 172-177.
    PubMed  |  
  56. Johnson, D.A., 1999. Esophageal Involvement in other Inflammatory Conditions. In: The Esophagus, Castell, D.O. and J.E. Richter (Ed.). Williams and Wilkins, Philadelphia, pp: 565-580.
  57. Johnson, D.A., 1999. Alteration in visceral perceptions represent primary pathophysiology in chest pain of unexplained etiology. Practical. Gastronterol., 23: 70-78.
  58. Johnson, D.A. and Z. Younes, 1999. Symptoms in gastroesophageal reflux disease. Gastroenterol Clin NA, 28: 809-830.
  59. Johnson, D.A. and Z. Younes, 1999. Complications of endoscopy. J. Clin. Gastroenterol, 29: 306-317.
  60. Younes, Z.H., D.A. Johnson and L. Dimick, 1998. Sigmoid anal intussusception presenting as rectal prolapse: Role of endoscopic diagnosis. Gastrointest Endosc, 47: 561-563.
    PubMed  |  
  61. Johnson, D.A., 1998. Intestinal spirochetosis. Gastroenterol. Observer, 17: 2-8.
  62. Johnson, D.A., 1998. Fecal occult blood testing-problems, pitfalls and diagnostic concerns. Postgrad Med., 85: 287-299.
  63. Elsakr, R., D.A. Johnson, Z. Younes and E.C. Oldfield, 1998. Antimicrobial treatments of intraabdominal infection. Digestive Dis., 16: 47-60.
    CrossRef  |  
  64. Johnson, D.A., 1997. Gastroesophageal reflux disease: Short-term management strategies. Consultant, 37: 1329-1348.
  65. Johnson, D.A., 1997. Gastroesophageal reflux disease: Long-term management strategies. Consultant, 37: 1833-1844.
  66. Johnson, D.A., 1997. Congenital esophageal stenosis. Gastroenterology Observer, 14: 2-4.
  67. Johnson, D.A. and Z.Younes, 1997. Molecular and genetic advances in gastrointestinal cancer: State of the art. Digestive Dis., 15: 275-301.
    PubMed  |  
  68. Johnson, D.A., 1996. New dimensions in Helicobacter pylori infection. Emergency Med., 28: 74-86.
  69. Johnson, D.A., 1996. Medical therapy of GERD: Current state of the art. Hospital Practice, 31: 135-148.
    PubMed  |  
  70. Johnson, D.A., 1996. Helicobacter pylori: Issues and answers. Consultant, 36: 1911-1923.
  71. Fennerty, M.B., D. Castell, A.M. Fendrick, M. Halpern and D. Johnson et al., 1996. The diagnosis and treatment of Gastroesophageal Reflux Disease in a managed care environment. Arch. Int. Med., 156: 477-484.
    PubMed  |  
  72. Johnson, D.A., 1995. When and how to treat Helicobacter pylori infection. Family Practice Recertification, 17: 44-59.
  73. Johnson, D.A., 1995. The gastric volvulus. Gastroenterol. Observer, 14: 2-8.
  74. Wootton, F.T. and D.A. Johnson, 1994. GI bleeding in geriatric patients. Contemporary Gastroenterol., 18: 11-17.
  75. Johnson, D.A., 1994. Protean manifestations of intraabdominal lymphoma. Gastroenterol. Observer, 13: 2-8.
  76. Johnson, D.A., 1994. Deciphering the cryptic nature of GERD-induced cough. Am. J. Gastroenterol., 89: 1594-1595.
    PubMed  |  
  77. Collen, M.J., D.A. Johnson and M.J. Sheridan, 1994. Basal acid output and gastric hypersecretion in gastroesophageal reflux disease: correlation with ranitidine therapy. Diges. Dis. Sci., 39: 410-417.
  78. Lawson, M.J. and D.A. Johnson, 1993. Gastritis. In: Manual of Clinical Problems in Gastroenterology, Van Ness, N.M. and S.J. Chobanian (Eds.). Little, Brown and Company, Boston, MA., pp: 48-51.
  79. Lawson, M.J. and D.A. Johnson, 1993. Gastric Ulcer. In: Manual of Clinical Problems in Gastroenterology, Van Ness, N.M. and S.J. Chobanian (Eds.). Little, Brown and Company, Boston, MA., pp: 51-54.
  80. Johnson, D.A., 1993. Colon cancer screening issues. Forum, 8: 2-7.
  81. Johnson, D.A., 1993. Chronic Diarrhea. In: Manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and N.M. van Ness (Eds). Little, Brown and Company, Boston, MA., pp: 91-96.
  82. Johnson, D.A., 1993. Barrettss Esophagus. In: Manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and N.M. van Ness (Eds.). Little, Brown and Company, Boston, MA., pp: 28-32.
  83. Johnson, D.A., 1992. Noncardiac Chest Pain. In: Medicine for the Practicing Physician, Hurst, J.W. (Ed)., Butterworth Publishers, United Kingdom, pp: 1471-1473.
  84. Johnson, D.A., 1992. Medical therapy of gastroesophageal reflux. Am. J. Med., 52: 88-92.
  85. Johnson, D.A., 1992. Diffuse Esophageal Spasm. In: Medicine for the Practicing Physician, Hurst, J.W. (Ed)., Butterworth Publishers, United Kingdom, pp:1473-1477.
  86. Johnson, D.A. and E.L. Cattau, 1992. Hepatopulmonary syndrome: Qualification of the defect. Am. J. Gastroenterol., 87: 401-402.
    Direct Link  |  
  87. Collen, M.J and D.A. Johnson, 1992. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig. Dis. Sci., 37: 570-576.
    PubMed  |  
  88. Johnson, D.A., 1991. Screening colonoscopy: Is it time for the wave? Am. J. Gastroenterol., 86: 784-785.
  89. Johnson, D.A., 1991. Nonulcer Dyspepsia. In: Handbook of Experimental Pharmacology, Collen, M.J. and S.B. Benjamin (Eds.). Springer, Berlin, Heidelberg, New York, pp: 229-261.
  90. Johnson, D.A., 1991. Noncardiac chest pain. Forum, 6: 14-21.
  91. Johnson, D.A., 1991. Esophageal Involvement in other Inflammatory Diseases. In: Clinical Esophagology, Castell, D.O. (Ed.). Little, Brown and Company, Boston, MA., pp: 687-704.
  92. Cattau, E.L. Jr., D.O. Castell, D.A. Johnson, T.J. Spurling, R. Hirszel, S.J. Chobanian and J.E. Richter, 1991. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am. J. Gastroenterol., 86: 272-276.
    PubMed  |  
  93. Johnson, D.A., 1990. The evaluation and management of extrahepatic obstructive jaundice. Forum, 5: 1-9.
  94. Drane, W.E. and D.A. Johnson, 1990. Sincalide-augmented quantitative hepato-biliary scintigraphy definition of normal parameters and evaluation of biliary dyskinesia. J. Nucl. Med., 31: 1462-1468.
  95. Johnson, D.A., W.E. Drane, J.C. Curran, A. Khan, C.A. Cianleglio, E.L. Jr. Cattau and S.B. Benjamin, 1989. Gastroesophageal reflux and pulmonary function tests in progressive systemic sclerosis. Arch. Intern. Med., 149: 589-593.
  96. Johnson, D.A., 1989. Calcium Channel Blockers. In: Manual of Gastrointestinal Pharmacology, Van Ness, M.N. and M.S. Gurney (Eds.). Little, Brown and Company, Boston, MA., pp: 365-374.
  97. Johnson, D.A., 1989. Antispasmodic Agents. In: Manual of Gastrointestinal Pharmacology, Van Ness, M.N. and M.S. Gurney (Eds.). Little, Brown and Company, Boston, MA., pp: 320-329.
  98. Johnson, D.A., 1989. Diarrhea in critically ill patients. Am. Fam. Physician, 3: 392-410.
    PubMed  |  
  99. Johnson. D.A. and E.L. Jr. Cattau, 1988. Gastrointestinal Drugs in the Critically Ill Patient. In: The Pharmacologic Approach to the Critically Ill Patient, Chernow, B. (Ed.). Williams and Wilkins, Baltimore, MD., pp: 322-346.
  100. Winters, C., T.J. Spurling, S.J. Chobanian, D.J. Curtis and R.L. Esposito et al., 1987. Barrett's esophagus: A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology, 92: 118-124.
    PubMed  |  
  101. Winters, C. and D.A. Johnson, 1987. Barrett´┐Żs esophagus. N. Eng. J. Med. (Lett.), 316: 276-277.
  102. Karvelis, K.C., W. Drane, D.A. Johnson and E.D. Silverman, 1987. Barrett's esophagus: Decreased clearance shown by radionuclide esophageal scintigraphy. Radiology, 162: 97-99.
    PubMed  |  
  103. Johnson, D.A., W.E. Drane, J. Curran, S.B. Benjamin, S.J. Chobanian, K. Karvelis and E.L. Jr. Cattau, 1987. Metoclopramide response of esophageal and gastric motor abnormalities in patients with progressive systemic sclerosis. Arch. Intern. Med., 147: 1597-1601.
  104. Johnson, D.A., J.R. Hacker, S.B. Benjamin, S.J. Chobanian, M.M. van Ness and E.L. Jr. Cattau, 1987. Percutaneous endoscopic gastrostomy effects on gastroesophageal reflux and the lower esophageal sphincter. Am. J. Gastroenterol., 82: 622-624.
    PubMed  |  
  105. Johnson, D.A., G. Winters, W.E. Drane, E.L. Cattau, S.J. Chobanian and A. Dubois, 1987. Solid phase gastric emptying in Barrett's esophagus. Dig Dis. Sci., 9: 23-27.
  106. Johnson, D.A., E.L. Cattau, A. Khan, S.J. Chobanian and D. Newell, 1987. Fiberoptic endoscopy in a nasopharyngeal intubation. Gastrointest Endosc, 33: 32-33.
  107. Johnson, D.A., A.M. Diehl, M.H. Sjogren, J. Lazar, E.L. Jr. Cattau and R.C. Smallridge, 1987. Serum angiotensin converting enzyme activity in evaluation of patients with liver disease. Am. J. Med., 83: 256-260.
    PubMed  |  
  108. Johnson, D.A., 1987. Gastritis. In: Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA., pp: 40-43.
  109. Johnson, D.A., 1987. Chronic Diarrhea. In: Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA, pp: 86-90.
  110. Johnson, D.A., 1987. Barrett's Esophagus. In: A manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and M.M. van Ness (Eds)., Little, Brown and Company, Boston, MA., pp: 22-26.
  111. Johnson, D.A. and E.L. Cattau, Jr., 1987. Gastric Ulcer. In: A Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA, pp: 43.
    CrossRef  |  
  112. Hacker, J.F., S.J. Chobanian, D.A. Johnson, C. Winters and E.L. Cattau, 1987. Patient acceptability of per gastrointestinal radiography versus endoscopy. South J. Med., 80: 1091-1093.
  113. Drane, W.E., K.C. Karvelis, D.A. Johnson and E.D. Silverman, 1987. Scintigraphic evaluation of duodenogastric reflux. Problems, pitfalls, and technical review. Clin. Nucl. Med., 12: 377-384.
    PubMed  |  
  114. Drane, W.E., G.A. Krasicky and D.A. Johnson, 1987. Radionuclide imaging of primary tumors and tumor-like conditions of the liver. Clin. Nucl. Med., 12: 569-582.
    PubMed  |  
  115. Drane, W.E., D.A. Johnson, K.C. Karvelis, J. Curran and E.D. Silverman, 1987. Metoclopramide effects on esophageal function. J. Nucl. Med., 28: 810-815.
  116. Drane, W.E., D.A. Johnson and E.L. Cattau, 1987. Scintigraphic assessment of nutcracker esophagus: A reevaluation. Radiology, 163: 33-38.
  117. Chobanian, S.J., E.L. Cattau, D.A. Johnson, C. Winters and M.M. van Ness, 1987. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus. Gastro Endosc, 33: 99-101.
    PubMed  |  
  118. Cattau, E.L. Jr. and D.A. Johnson, 1987. Postcholecystectomy Syndrome. In: A Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds.). Little, Brown and Company, Boston, pp: 220-222.
  119. Johnson, D.A., J. Hancock and E.L. Cattau Jr., 1986. Pediatric primary sclerosing cholangitis. Dig. Dis. Sci., 31: 773-777.
    CrossRef  |  Direct Link  |  
  120. Johnson, D.A., E.L. Cattau Jr. and H.F. Zimmerman, 1986. Dapsone hepato-toxicity. Arch. Intern. Med., 146: 875-877.
  121. Johnson, D.A., E.L. Cattau Jr. and C. Winters Jr., 1986. Biliary dyskinesia with associated high amplitude esophageal peristaltic contractions. Am. J. Gastroenterol., 81: 254-256.
    PubMed  |  
  122. Johnson, D.A., C. Winters, T.J. Spurling, S.J. Chobanian and E.L. Cattau, 1986. Esophageal acid sensitivity in Barrett's esophagus. J. Clin. Gastro., 31: 1217-1220.
  123. Johnson, D.A. and E.L. Cattau Jr., 1986. Stool chemistries in evaluation of diarrheal disorders. Am. Fam. Physician., 33: 131-134.
  124. Johnson, D.A. and C. Everhart, 1986. Colitis in Bechet's syndrome. Gastrointest Endosc., 32: 9-60.
  125. Drane, W.E., K. Karvelis, D.A. Johnson, J.J. Curran and E.D. Silverman, 1986. Progressive systemic sclerosis: Radionuclide esophageal scintigraphy and manometry. Radiology, 160: 73-76.
    PubMed  |  
  126. Chobian, S.J., C. Winters Jr., D.A. Johnson, W. Martland, J.L. Buck and E.L. Cattau Jr., 1986. Esophageal pseudoworm: Pasta not parasite. Ann. Intern. Med., 105: 138-138.
    PubMed  |  Direct Link  |  
  127. Johnson, D.A., S.J. Chobanian and E.L. Cattau Jr., 1985. Physiology of hyper-salivation syndrome. J. Am. Med. Assoc., 253: 2831-2832.
  128. Johnson, D.A., P.W. Stafford and R.J. Volpe, 1985. Ischemic bowel infection and phenylpropanolamine. J. Med., 142: 399-400.
  129. Johnson, D.A., K.F. Wagner and J. Blanks, 1985. False-positive direct fluorescent antibody testing for Legionella. J. Am. Med. Assoc., 253: 40-41.
    CrossRef  |  Direct Link  |  
  130. Johnson, D.A., E.L. Cattau Jr. and J. Hancock, 1985. Primary crohn's disease of the oropharynx. Ear Nose Throat, 64: 43-46.
  131. Johnson, D.A., A.M. Diehl, F. Finkelman and E.L. Cattau Jr., 1985. Crohn's disease and systemic lupus erythematosus. Am. J. Gastroenterol., 80: 869-870.
  132. Johnson, D.A. and T.V. Whalen, 1985. Lactic acidosis and neoplastic diseases. Military Med., 150: 206-208.
  133. Johnson, D.A. and K.F. Wagner, 1985. Antibiotic therapy based on stained peripheral blood smear. Arch. Intern. Med., 145: 369-370.
    CrossRef  |  
  134. Johnson, D.A., P. Aulicino and J.G. Newby, 1984. Bacillus cereus-induced myonecrosis. J. Trauma, 24: 267-270.
    CrossRef  |  PubMed  |  
  135. Johnson, D.A., K. Wagner and J. Blanks, 1984. Diagnosis of legionnaire's disease. J. Am. Med. Assoc., 251: 3079-3080.
  136. Johnson, D.A., H. Etter and D. Reeves, 1983. Stroke and phenylpropanolamine use. Lancet, 2: 970-970.
  137. Johnson, D.A. and T.V. Whalen, 1983. Toxic tricyclic antidepressant levels and the EEG. JAMA, 250: 1027-1027.
  138. Johnson, D.A. and T. Parlette, 1983. Insulin-induced hyperlipodystrophy. Cutis, 32: 273-276.
  139. Johnson, D.A. and M. Bohan, 1983. Propoxyphene withdrawal with clonidine. Am. J. Psychiatry, 140: 1217-1218.
    PubMed  |  Direct Link  |